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The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This
lag resembles those encountered with monoclonal antibodies,
gene therapies, and many biological targets and is consistent
with studies of innovation showing that technology maturation
is a critical determinant of product success. We previously
described an analytical model for the maturation of biomedical
research, demonstrating that the efﬁciency of targeted and biological development is connected to metrics of technology
growth. The present work applies this model to characterize
the advance of oligonucleotide therapeutics. We show that
recent oligonucleotide product approvals incorporate technologies and targets that are past the established point of technology growth, as do most of the oligonucleotide products
currently in phase 3. Less mature oligonucleotide technologies,
such as miRNAs and some novel gene targets, have not passed
the established point and have not yielded products. This analysis shows that oligonucleotide product development has
followed largely predictable patterns of innovation. While technology maturation alone does not ensure success, these data
show that many oligonucleotide technologies are sufﬁciently
mature to be considered part of the arsenal for therapeutic
development. These results demonstrate the importance of
technology assessment in strategic management of biomedical
technologies.

INTRODUCTION
With the recent approval of the antisense therapeutic nusinersen for
the treatment of spinal muscular atrophy, jointly developed by Biogen
and Ionis Pharmaceuticals, oligonucleotide technologies may have
ﬁnally yielded a clinically and commercially successful biopharmaceutical product. This long-anticipated success was the subject of a
series of recent review articles that have chronicled the difﬁcult,
30-year path that led to this important milestone.1–4
The long path from salient scientiﬁc discoveries to successful products should not be unfamiliar to those who follow biotechnology.
As previous reviews have noted, the >30-year interval between the
emergence of oligonucleotide technologies in the 1980s and the present successes is similar to the decades-long lag between the ﬁrst
description of hybridoma technologies by Kohler and Milstein in
the early 1970s and approval of Rituxan, the ﬁrst successful commer-

cial antibody product, in the late 1990s. Similar lags have been seen
between discoveries of molecular targets and the ﬁrst approval of
products associated with those targets. For example, there was
a >20-year lag between the ﬁrst description of the tyrosine kinase activity of retroviral oncogenes in the 1970s and approval of the ﬁrst
tyrosine kinase inhibitor, and there was a similar lag between the discovery of tumor necrosis factor (TNF) in 1975 and approval of the
ﬁrst TNF inhibitors. These are not isolated examples. A recent analysis of 113 ﬁrst-in-class products by Eder et al. showed that there has
been, on average, a 22-year lag between publication of research
describing a novel drug target, therapeutic concept, or chemotype
and ﬁrst approval of a therapeutic product associated with this
research.5 These data are consistent with the average 17-year lag
noted in a 2011 literature review from RAND Europe6 and the
18-year lag between basic research funding and new drug approvals
incorporated in an economic model of drug discovery and development by the Congressional Budget Ofﬁce.7
The recent series of expert reviews chronicled a long series of insights,
false starts, successes, and failures that mark the path from the initial
discoveries of nucleotide therapeutics to the approval of nusinersen.1–4,8 Analogous expert reviews have been written for other
technologies that experienced decades-long lags between an enabling
scientiﬁc insight or invention and approval of a ﬁrst-in-class therapeutic based on that advance. For example, the ability to make monoclonal antibodies, ﬁrst described by Kohler and Milstein, only generated therapeutic products when their methods for producing murine
antibodies was supplanted by methods for producing chimeric, humanized, and, ﬁnally, fully human monoclonal antibodies,9 while
the discovery of TNF only led to anti-TNF therapeutics after the failure of TNF as a cancer therapy and recognition of the role played by
TNF in arthritis and other inﬂammatory disorders.10 While this type
of analysis by experts in a ﬁeld can faithfully relate the complex, and
often convoluted, path of translational science, such post hoc reﬂections have not produced a generalized explanation for the characteristic innovation lag between scientiﬁc insights and inventions and ﬁrst
approval of successful therapeutic products based on this science.6
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Figure 1. Schematic of TIME Model for Technology Growth
Technology growth is modeled as an S curve using an exponentiated logistic
function (solid green line) fit to cumulative publications (N) in a PubMed search. The
technology initiation point (Ti) is calculated as the point of maximum acceleration
of publication activity (maximum d2N/dx2), representing the beginning of a phase
of exponential growth. The established point (Te) is calculated as the point of
maximum slowing of publication activity (minimum d2N/dx2), representing the end of
the phase of exponential growth and slowing as the technology approaches its
limits.

A 2011 RAND report highlighted the importance of such an understanding in concluding: “Despite their policy salience, little is known
about time lags and how they should be managed. This lack of knowledge puts those responsible for enabling translational research at a
disadvantage.6”
Explanations for this characteristic lag have come from research on
the process of innovation itself, including the roles of organizational
behavior, strategy, social networks, and technology management and
the dynamics of scientiﬁc, intellectual, human, and economic capital
in the innovation ecosystem. One aspect of this research has focused
on the temporal relationship between scientiﬁc and technological
progress and successful product development, demonstrating that
technological maturation or “readiness” is a critical determinant in
the ability to develop successful products. A 1999 General Accounting
Ofﬁce report on the management of technologies noted, for example:
“..no element is more important than having technology, advanced
enough to meet requirements but also mature enough to be predictably managed, available at the start of the product development cycle.
Maturing new technology before it is included on a product is perhaps
the most important determinant of the success of the eventual product.11” As a result, strategic technology management often uses tools
such as technology roadmapping12, technological forecasting,13,14 or
technology readiness assessment15–17 to assess the maturation of critical path technologies and their ability to satisfy the performance
speciﬁcations for innovative products over time.
While most of this research involves computers and communication
technologies, mechanical engineering, aerospace engineering, or defense systems, we have applied these theories18–20 to develop analogous models for biopharmaceutical development. Speciﬁcally, we
have asked whether the characteristic lag between biomedical discoveries and successful biopharmaceutical development is analogous to
the lag related to technological maturation or readiness observed in
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other technology sectors.21–25 Studies have shown that many different
technologies mature through a characteristic “S curve,19,26,27” in
which an initial insight or invention initiates a period of exponential,
technological advance, which slows as the technology approaches its
limits. Our initial studies suggested that there were qualitative parallels between patterns of innovation observed in other technology sectors and the accumulation of publications for monoclonal antibodies,
nucleotide therapeutics, and gene therapies.21 We then described a
bibliometric-based analytical model, the Technology Innovation
Maturation Evaluation model (“TIME model”), which allows for a
quantitative assessment of research maturation based on publication
activity over time. Brieﬂy, the model posits that peer-reviewed
research papers embody a quantum of new knowledge related to
a research area; some represent positive contributions, while
others may represent insigniﬁcant, or even negative, contributions.
Integrated over large numbers of published papers, the number of
publications may be considered a metric for the advance of that technology. We have applied this model to more than 200 discrete drug
targets along with technologies for monoclonal antibodies and gene
therapies and have shown that the accumulation of publications for
the large majority of technologies examined can be modeled as an
exponentiated logistic function (“S curve”).22–24,28 This curve is characterized by a point of initiation (“Ti”) representing the point of
maximum acceleration into a period of exponential growth, which
slows as the technology passes an established point (“Te”), deﬁned
as the point of maximum slowing, and approaches a limit (Figure 1).
The analytically deﬁned point of initiation and the established point
provide objective, quantitative metrics for asking whether successful
development of biopharmaceutical products is linked to maturation
of associated technologies, as observed in other technology sectors.
In studies of >400 new molecular entities (NMEs) using the TIME
model, we have shown that few products discovered using targeted
screening or biological products are approved before the associated
technologies pass the established point,23–25 and that interval between
the initiation point of a new research area and ﬁrst approval of a drug
based on this research is 36 years.24,25 In contrast, there was no association between metrics of technology growth and approval of product discovered through phenotypic methods.24,25 These observations
are consistent with the expectation that targeted discovery is based on
accumulated knowledge of potential drug targets and their relationship to disease processes, whereas phenotypic methods are not based
on such knowledge.29
These studies suggest that the characteristic lag between the initiation
of new areas of research and ﬁrst approval of biopharmaceutical
products based on this research is an intrinsic property of targeted
and biologic strategies for drug discovery and development. In this
report, we extend these studies to oligonucleotide therapeutics, asking
whether quantitatively similar patterns are evident in this ﬁeld. The
results suggest that innovation of oligonucleotide therapeutics has
followed largely predictable patterns, with successful products
emerging only after research related to the speciﬁc oligonucleotide
technology, component technologies, and the molecular targets past
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RNAi includes both small interfering RNAs (siRNAs) and
microRNAs (miRNAs) and involves the use of double-stranded
nucleotides, which are incorporated into an RNA-induced silencing
complex (RISC) that guides the nucleotides to complementary
mRNA sequences and alters post-transcriptional gene expression.
siRNAs are 21–23 nt long and degrade mRNA through precise
complementary binding and subsequent cleavage of the mRNA.
miRNAs are larger oligonucleotides that form stem-loop structures
with double-stranded segments, which are processed into smaller segments that imperfectly bind to a cRNA sequence and cause translational repression rather than cleavage of the mRNA.32 Aptamers
are single-stranded oligonucleotides designed to target proteins
rather than nucleic acids.33 CRISPR is also a nucleotide therapeutic,
but it does not target post-transcriptional gene expression; instead,
it uses nucleotide sequences as a guide for targeted gene editing.
We have included it in our analysis because it provides a complementary example of an early-stage, emerging technology. For the purpose
of this analysis, each of these approaches represent discrete, ordinal
technologies that arose from a discrete scientiﬁc insight or invention
with an identiﬁable, though sometimes overlapping, literature that
deﬁnes the design parameters, performance, optimization, and potential applications of that mechanism.

Figure 2. TIME Models for Growth of Oligonucleotide Technologies
(A) Annual publications in PubMed related to oligonucleotide therapeutics (markers)
and best fit TIME model (lines). The TIME model uses the best fit exponentiated
logistic function based on the cumulative number of publications (inset graph). Data
indicated with open markers could not be fit to this function. (B) The logistic
(“S curve”) representation of the TIME model is shown on a log scale. Note that the
apparent residuals are exaggerated at the low end of the log scale (see Materials
and Methods). Dates of FDA approval of oligonucleotide therapeutics are indicated,
including those for fomivirsen (1998, subsequently withdrawn from market), mipomersen (2013), nusinersen (2016), and eteplirsen (2016).

the established point. This analysis explores how the theoretical understanding of biomedical innovation can be used to inform more
efﬁcient product development and effective business strategy in the
future.

RESULTS AND DISCUSSION
Mechanism-Based Technologies for Oligonucleotide
Therapeutics

There have been many outstanding reviews of oligonucleotide technologies, which address the historical development of the ﬁeld, essential technologies, and the current state of clinical development.2,30 We
will not attempt to add to this literature.
Brieﬂy, oligonucleotide therapeutics are products composed of singleor double-stranded nucleotides and have many different mechanisms
of action. Antisense oligonucleotides are single-stranded nucleotides
designed to bind complementary mRNA sequences and alter splicing
(splice-switching oligonucleotides), suppress translation, or activate
RNase H cleavage of the mRNA. Ribozymes have a complex nucleotide structure that cleaves mRNA through RNA-mediated catalysis.31

We used the TIME model to characterize the growth of each technology (Figure 2). The annual and cumulative numbers of publications
are shown in Figure 2A. The exponentiated logistic function assumes
a logistic, S-curve form on log scales, as shown in Figure 2B.
For each curve, we assessed the validity of the initiation point by
examining the correspondence between the calculated initiation
point, which introduces the phase of exponential growth, and seminal
advances noted in expert reviews. Speciﬁcally, we found that many reviews of antisense technologies cite the 1978 work of Zamecnik et al.,
on the synthesis of a 13-mer antisense oligonucleotide34 as a seminal
contribution. Similarly, seminal events in the initiation of ribozyme
technologies include the Nobel-prize-winning work by Cech, published in 1982,35 and of Altman, published in 1983.36 Each of these
dates are within close proximity of the calculated Ti of 1980 for these
technologies. The discovery of RNAi originated in the mid-1990s with
experimental work in petunias37 and C. elegans.38 While these dates
are somewhat later than the calculated Ti of 1991, this is consistent
with the expectation that prior work on oligonucleotide therapeutics
made a contribution to the rate of growth of RNAi.
Figure 2B shows that three technologies—antisense, ribozymes, and
RNAi—exhibit an “S-curve pattern” of growth. Both antisense and
ribozymes passed the point of maximum slowing, the established
point, in the mid-1990s; RNAi technology reached this point a
decade later. Two technologies shown in Figure 2, microRNA and
CRISPR, do not exhibit an exponential pattern of growth and could
not be modeled with the TIME model. These more recent technologies exhibit an exponential, or near-exponential, growth pattern
characteristic of technologies that have not yet reached the established point.
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pharmacodynamic properties of the oligonucleotide, efﬁcient
manufacturing and control, chemical stability, and delivery.2,3,30,31,40
These include phosphorothioate chemistry, locked and bridged
nucleic acids, phosphorodiamidate morpholino chemistry, 20 -OME
chemistry, and phosphotriester oligonucleotide chemistry. Many delivery technologies have been studied that were not addressed in this
study.

Figure 3. TIME Models for Growth of Component Technologies and
Biological Targets
Top: cumulative publications (markers) and best fit exponentiated logistic functions
(lines) are shown for chemistries incorporated in approved oligonucleotide therapeutics. Open markers indicate datasets that could not be fit with the TIME model.
Bottom: cumulative publications (markers) and best fit exponentiated logistic
functions (lines) are shown for the biological targets of approved oligonucleotides.
Dates of FDA approval of oligonucleotide therapeutics are indicated in color corresponding to their biological target.

Component Technologies for Oligonucleotide Therapeutics

A feature of technology growth cycles is the premise that technological progress occurs as limits of precursor or invention-stage
technologies are reached and new ordinal technologies emerge.39
Oligonucleotide therapeutics emerged from basic research on
mRNA function and processing as well as the observation that exogenously administered nucleotides could interfere with cognate gene
expression or translation in various in vitro and in vivo systems.
McNamee and Ledley observed that the rapid growth of this ﬁeld
was enabled by the emergence of several enabling technologies,
including automated oligonucleotide synthesis, transfection, and
delivery. This sequential emergence of ordinal technologies can be
approximated by a logistic S-curve; in this case, the TIME model.
The growth cycles of oligonucleotide therapeutics are generally understood to be inﬂuenced by several challenges, including chemical
synthesis, stability, and therapeutic delivery.2,3,30,31,40 Additionally,
the understanding of the effect of synthetic oligonucleotides on human biology, such as its interaction with the innate immune system,
has also been critical to the development of drugs that were safe for
administration and also opened novel mechanisms of action for a
new class of immune-active drugs.41
Much of the focus on research and development of oligonucleotide
therapeutics has focused on novel chemistries that improve the
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TIME analysis was done to examine the technology growth of
several ordinal technologies that have been utilized in the current
approved therapeutics, which include phosphorothioate chemistry,
phosphorodiamidate morpholino chemistry, 20 -O-methoxyethyl
(20 -MOE) chemical modiﬁcations, and locked nucleic acid (LNA)
(Figure 3A). While the applicability of TIME models to growth of
chemistry technologies has not been previously investigated, these
few test cases do show the S-curve pattern. Many of these technology growth cycles were concurrent or occurred after antisense
oligonucleotide, ribozyme, and RNAi growth cycles. As broader understanding of oligonucleotide therapeutic technology matured, the
underlying chemical technologies also matured and represent a
necessary step toward successful drug development for project-speciﬁc approaches.
Molecular Targets for Oligonucleotide Therapeutics

In addition to the growth cycles of ordinal chemical and delivery
technologies, oligonucleotide therapeutic development is also affected
by project-speciﬁc biological targets. From Pharmaprojects searches,
the biological targets for therapeutic candidates that have reached
phase 3 or approval were identiﬁed, resulting in 19 unique targets.
TIME model analysis shows that the biological targets that are reaching phase 3 are relatively mature (Table S1). The TIME models for
biological targets of approved antisense oligonucleotide therapeutics
show that matured biological targets are correlated with the successful
launch of a product. Interestingly, the launch of fomivirsen was ahead
of the established point of its biological target (CMV-IE2) and
antisense oligonucleotides and was subsequently withdrawn from
the market. The more recent approvals more closely align with the
established points of their underlying technology growth cycles.
(Figure 3B).
Approval and Development of Oligonucleotides in Context

Research on innovation in many different technology sectors has
shown that there are characteristic patterns to the process by which
scientiﬁc and technological advances are translated into novel products. One such pattern is the recurring relationship between the maturation of technologies and the ability to develop successful products
based on those technologies. The present data suggest that similar
patterns may be evident in the emergence of oligonucleotide therapeutics. There are several dimensions to this association.
The ﬁrst dimension concerns the series of distinct oligonucleotide
technologies. While there are many commonalities to antisense,
ribozymes, RNAi, and miRNA, the ordinal succession of these
technologies does not reﬂect sequential improvement on previous

www.moleculartherapy.org

Figure 4. TIME Models for Growth of Technologies
for Oligonucleotide Therapeutics in Phase 3 Clinical
Trials and Their Biological Targets
Best fit exponentiated logistic functions are shown (lines).
Open markers indicate datasets that could not be fit with
this function. (A) Antisense products in phase 3. (B) RNAi
products in phase 3. (C) Ribozyme products in phase 3.
(D) Aptamer products in phase 3.

established point, and was subsequently withdrawn from the market in 2006. This experience
parallels the launch of the ﬁrst monoclonal antibody product, Orthoclone OKT3 (muromonabCD3), a murine monoclonal antibody that was
approved before monoclonal antibody technologies reached the established point and that
was subsequently withdrawn from the market.
Both experiences are consistent with observations in other technology sectors that immature
technologies may be able to produce products;
however, those products are less likely to be
able to compete with products developed from
mature technologies. In contrast, the recent approvals of mipomersen in 2013 and of nusinersen and eteplirsen in 2016 came well after
the established point of antisense technologies.

technologies the way that chimeric, humanized, and fully human
monoclonal antibodies each improved on previous technologies.21
In this context, the emergence of nucleotide therapies more closely
resembles the growth of gene therapy, which has involved a series
of distinct technologies, including retrovirus-, adenovirus-, adenoassociated-virus-, and lentivirus-based vectors.22 While there is
clearly more overlap between the ordinal oligonucleotide technologies than those for gene therapy, we have modeled the growth of
each oligonucleotide technology separately in assessing the relationship between technology maturation and product approvals.
This analysis suggests that the emergence of antisense therapeutics
exhibits the same pattern seen previously for monoclonal antibodies
and drug targets. The ﬁrst oligonucleotide therapeutic to be approved,
Vitravene (fomivirsen) received Food and Drug Administration
(FDA) approval in 1998, before antisense technologies reached the

The second dimension concerns the drug target.
A series of papers examining patterns of innovation for more than 400 NMEs has demonstrated
a consistent relationship between metrics
describing the growth of research on drug targets and ﬁrst approval of targeted and biological
NMEs.23–25 This analysis of RNA therapeutics
shows that each of the approved oligonucleotides involves targets that had progressed past
the established point when the products were
developed (Figure 3). Furthermore, our data suggest that, independent of the maturation of oligonucleotide technologies, there are
few, if any, targeted therapeutics approved until research on the target
has matured. Finally, TIME model evaluation of biological targets in
phase 3 development for antisense, RNAi, and ribozyme therapeutics,
as determined from Pharmaprojects, shows few to no immature technologies making it to phase 3 (Figure 4).
The third dimension involves the nucleotide chemistries that
have proved essential to producing oligonucleotide therapeutics
with acceptable pharmaceutical and pharmacodynamic properties.
We have not previously applied our bibliometric-based TIME model
to chemical technologies, nor do we think that bibliometric-based
metrics are the best measure of such technologies, since chemical
properties of oligonucleotides can be readily measured against
parameters required by the product design. Nevertheless, Figure 3B
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shows that a series of chemical technologies that are incorporated
in recently approved products are no longer in an exponential
growth phase and have passed the point that would be considered
established.
Taken together, this analysis suggests that the long-awaited success
of oligonucleotide therapeutics exhibits a pattern that is quantitatively similar to the characteristic patterns observed in other technology sectors as well as previous studies of biopharmaceutical
development using the TIME model.23–25 These results suggest
that the lag in developing such products reﬂects, at least in part,
an intrinsic property of technological innovation. In this context,
it should be noted that the established point identiﬁed by the
TIME model is the point of maximum slowing of publication activity, most of which reﬂects basic research, as opposed to research on
speciﬁc processes or products. This slowing may reﬂect a point in
the advance of this basic science when research achieves a more
nuanced and detailed understanding of the system but produces
fewer unpredictable results, leading to large numbers of publication,
and may diminish grant support. If so, this point would also represent a stage when the science is sufﬁciently advanced to provide
meaningful validation of molecular targets, selection of lead compounds, and achievable clinical indications, which are essential
determinants of product success.
Technological maturation is not sufﬁcient for successful product
development. There are many reasons that products fail in clinical trials; not only inadequate efﬁcacy relative to placebo or existing therapies, but also unexpected, sometimes idiosyncratic, side effects as well
as “commercial failures” when sponsors choose to discontinue development for strategic reasons or concern about economic viability of
the product.42 It may also be true that certain technologies, even
when mature, prove not to have utility for drug discovery and development. Mipomersen, for example, has achieved limited sales despite
FDA approval because small molecules continue to have signiﬁcant
advantage over oligonucleotides in terms of oral administration and
cost. Certain molecular targets are traditionally considered “undruggable,” despite intensive research and development efforts,43 and
technologies for murine monoclonal antibodies as well as gene therapy using murine retroviral vectors have been abandoned in favor of
superior technologies. Ribozymes may prove to be an example of a
technology that, even when fully mature, will not generate products
that are competitive with other oligonucleotide technologies, biological products, or small molecules.

lems afterward. In this sense, technology maturity breeds product
success.11”
The present results suggest that oligonucleotide technologies have
now matured to a level equivalent to that of monoclonal antibodies
when those technologies ﬁrst achieved commercial success. Moreover, our analysis of oligonucleotide therapeutics currently in phase
3 clinical trials shows a robust development pipeline comprising
products that incorporate oligonucleotide technologies and address
targets that have passed the established point of technology growth.
We did note that the targets for RNAi products in development are
somewhat less mature than those being targeted by antisense technologies (Figure 4). The present results also suggest that newer oligonucleotide technologies, including miRNA, are signiﬁcantly less mature
than other technologies that have generated successful biopharmaceutical products (Figure 2B).
Our conclusion is not that innovators or investors can be sanguine
about success of oligonucleotide technologies in the future; only
that the maturation of critical path technologies should be a factor
in the design of candidate therapeutics and in assessing the opportunity and risk of biopharmaceutical technologies, as it is in other
technology sectors. The present results suggest that there are
recurring patterns to the maturation of basic research on various
oligonucleotide technologies and potential targets for these products. As such, these results are similar to those of others who
have characterized the progression of research on RNAi from an
initiating MeSH domain to the subsequent expansion of research
to other research domains.44 We suggest that these observations
might be extended with the application of machine learning
and artiﬁcial intelligence to develop expert systems that are useful
in assessing the maturation of technologies as part of the decision
to proceed with development of products based on these
technologies.
These results also point to the need for caution in designing initiatives
aimed at accelerating translational science. These initiatives should
accelerate the maturation of science to the point that it can sustain
successful product development, and they do not prematurely
advance candidate products into development that are associated
with immature technologies. As noted in our analysis of gene therapy,
the failure of investments and clinical investigations of immature
technologies can create unwarranted pessimism concerning these
technologies and stall successful development.22

Implications for Strategic Management of Future Development

MATERIALS AND METHODS

In other technology sectors, management tools such as technology
roadmapping, technology forecasting, and technology readiness
assessment enable managers and investors to consider the state of
maturation of enabling technologies in product design and development. The previously referenced report from the Government
Accountability Ofﬁce (GAO) summarized the importance of these
tools: “.resolving technology problems before product development
begins results in 10 times the savings compared to correcting prob-

Data Sources
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Pharmaprojects was used to identify oligonucleotide therapeutics that
are in development, have been approved, or have been recently discontinued that were designed to work by antisense, RNAi, or ribozyme. For each candidate product, data on the therapeutic target,
stage of development, and the licensee and originator companies
(current to May 2017) were retrieved. Component technologies that
are incorporated into the design of these oligonucleotide therapeutics

www.moleculartherapy.org

were ascertained from literature review. The list of products and
associated technologies is shown in Table S1.
TIME Analysis

We identiﬁed publications in PubMed associated with oligonucleotide technologies and the mechanism of action of these therapeutics,
as well as the biological targets and component technologies associated with approved products or candidate products in phase 3 trials.
Boolean search terms and NCBI Query Translations were optimized
to minimize incomplete ascertainment of relevant papers due to
immature vocabularies as well as identiﬁcation of research on unrelated topics for each technology. These search terms are shown in
Table S1.
The TIME model ﬁts an exponentiated logistic function to the
cumulative number of publications over time, from the ﬁrst year of
continuous, annual publication through 2015, using methods
described previously21,24,28 (Figure 1). The exponentiated logistic
function has the form:

N =L

1

1+e



rðtt0 Þ

or

logN =

technology, the analytically deﬁned initiation point calculated from
the best-ﬁt TIME model was qualitatively validated by comparing
this date with seminal scientiﬁc milestones identiﬁed in expert reviews. The error range for Ti and Te is estimated from the mean of
the residuals.
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Supplemental Information includes one table and can be found with
this article online at https://doi.org/10.1016/j.omtn.2017.10.017.
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